Eli Lilly and Company (NYSE:LLY) expects 2025 revenue of between $58.0 billion – $61.0 billion. The midpoint demonstrates ~32% growth YoY, fueled by new Lilly medicines like Zepbound ...

Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

Eli Lilly's medicines, such as Mounjaro and Zepbound, are racking up incredible sales, and they are still on an upward path. Further, other recent launches should soon contribute to the drugmaker ...

Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment for diabetes and obesity.

Eli Lilly's medicines, such as Mounjaro and Zepbound, are racking up incredible sales, and they are still on an upward path. Further, other recent launches should soon contribute to the drugmaker ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...